PETROS PHARMACEUTICALS INC (PTPI)
US71678J2096 - Common Stock
PTPI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. PTPI may be in some trouble as it scores bad on both profitability and health. PTPI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PTPI had negative earnings in the past year.
In the past year PTPI has reported a negative cash flow from operations.
PTPI had negative earnings in each of the past 5 years.
PTPI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of PTPI (-66.00%) is worse than 65.64% of its industry peers.
PTPI's Return On Equity of -178.72% is on the low side compared to the rest of the industry. PTPI is outperformed by 71.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66% | ||
| ROE | -178.72% | ||
| ROIC | N/A |
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 74.18%, PTPI belongs to the top of the industry, outperforming 80.51% of the companies in the same industry.
PTPI's Gross Margin has declined in the last couple of years.
PTPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
2. Health
2.1 Basic Checks
PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTPI has more shares outstanding
PTPI has more shares outstanding than it did 5 years ago.
PTPI has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.44, we must say that PTPI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PTPI (-5.44) is worse than 63.59% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that PTPI is somewhat dependend on debt financing.
PTPI has a worse Debt to Equity ratio (0.55) than 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.44 |
ROIC/WACCN/A
WACC7.95%
2.3 Liquidity
PTPI has a Current Ratio of 1.89. This is a normal value and indicates that PTPI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.89, PTPI is not doing good in the industry: 67.69% of the companies in the same industry are doing better.
PTPI has a Quick Ratio of 1.74. This is a normal value and indicates that PTPI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.74, PTPI is doing worse than 64.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
The earnings per share for PTPI have decreased by -7.08% in the last year.
PTPI shows a strong growth in Revenue. In the last year, the Revenue has grown by 100.12%.
Measured over the past years, PTPI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)-7.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-212.73%
Revenue 1Y (TTM)100.12%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Revenue growth Q2Q627.8%
3.2 Future
PTPI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.61% yearly.
PTPI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.37% yearly.
EPS Next Y-16.7%
EPS Next 2Y8.39%
EPS Next 3Y11.61%
EPS Next 5YN/A
Revenue Next Year-26.46%
Revenue Next 2Y-14.21%
Revenue Next 3Y13.37%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PTPI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PTPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.39%
EPS Next 3Y11.61%
5. Dividend
5.1 Amount
No dividends for PTPI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PETROS PHARMACEUTICALS INC
NASDAQ:PTPI (4/26/2024, 10:23:19 AM)
0.6501
+0.01 (+1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.47M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66% | ||
| ROE | -178.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.18% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-7.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-16.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)100.12%
Revenue growth 3Y-15.24%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y